Article Sidebar

PDF
Issue: Vol. 56
Section: Research Article
DOI: 10.47972/vjcts.v56i.1791
Date Published: 31/07/2026
Views 83
Downloads 42
How to Cite
Le, P. L., Nguyen, M. T., & Lam, T. C. (2026). Endovascular drug-eluting stent placement for superficial femoral artery occlusive disease: midterm outcomes at a single centre. The Vietnam Journal of Cardiovascular and Thoracic Surgery, 56, 56 - 63. https://doi.org/10.47972/vjcts.v56i.1791

Endovascular drug-eluting stent placement for superficial femoral artery occlusive disease: midterm outcomes at a single centre

Phi Long Le1, Minh Tan Nguyen2, Thao Cuong Lam2,3,
1 University Medical Center Ho Chi Minh City
2 University Medical Center Ho Chi Minh City, Ho Chi Minh City
3 University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City

Main Article Content

Abstract

Background: The Eluvia drug-eluting stent (DES; Boston Scientific) — a paclitaxel-eluting nitinol stent with a sustained-release fluoropolymer coating — has demonstrated superior restenosis inhibition compared with bare-metal stents for superficial femoral artery (SFA) disease. Systematic data on midterm outcomes in the Vietnamese clinical setting remain limited.


Objective: To describe the clinical characteristics, lesion morphology, procedural parameters, and midterm outcomes (12- and 24-month Kaplan-Meier estimates) of Eluvia DES implantation for SFA occlusive disease at University Medical Center Ho Chi Minh City (UMC HCMC).


Patients and methods: Retrospective single-arm descriptive study analysing 71 consecutive patients who underwent Eluvia stent implantation between January 2021 and January 2024. Patency and survival rates were estimated using the Kaplan-Meier method.


Results: Mean age was 72.1 ± 9.4 years; 73.2% were male; mean BMI was 21.3 ± 2.9 kg/m². Comorbidities included diabetes mellitus (63.4%), hypertension (73.2%), and smoking (97.2%); 39.4% had chronic limb-threatening ischaemia (CLTI). Chronic total occlusion (CTO) accounted for 47.9% of lesions; mean DSA lesion length was 177 ± 98 mm; mean total stent length was 202.4 ± 46.7 mm (2.1 ± 0.8 stents/patient). Rutherford IV predominated (54.9%). Technical success was 100% by SVS criteria. Kaplan-Meier estimates at 12 and 24 months were: primary patency 90.1% and 73.2%; overall survival 94.3% and 84.5%; and freedom from clinically driven target lesion revascularisation (CD-TLR) 91.5% and 78.8%, respectively. ABI improved from 0.43 ± 0.18 to 0.83 ± 0.14 (p < 0.001).


Conclusion: Eluvia DES implantation for SFA occlusive disease is feasible with encouraging initial results at a Vietnamese tertiary cardiovascular centre. The single-arm retrospective design precludes comparative conclusions; prospective controlled studies are warranted.

Keywords

paclitaxel-eluting stent, superficial femoral artery, peripheral artery disease, chronic limb-threatening ischaemia, endovascular intervention

Article Details

References

1. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879–1888.
2. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267–276.
3. Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation. 2007;116(3):285–292.
4. Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial. JACC Cardiovasc Interv. 2009;2(12):1248–1259.
5. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133(15):1472–1483.
6. Conte MS, Bradbury AW, Kolh P, et al. Global Vascular Guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S–125S.
7. Kim J, Ko YG, Lee SJ, et al. Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease: K-ELUVIA Registry. Korean Circ J. 2024;54(9):565–576.
8. Stavroulakis K, Torsello G, Bosiers M, Argyriou A, Tsilimparis N, Bisdas T. 2-Year outcomes of the Eluvia drug-eluting stent for the treatment of complex femoropopliteal lesions. JACC Cardiovasc Interv. 2021;14(6):692–701.